. 2003 Feb 28;52(5):257–280. doi: 10.1007/s00262-002-0347-6

Table 5.

Rituximab (R) in combination with anthracycline-based regimens. RCD rituximab/cyclophosphamide/decadron, EPOCH etopside/vincristine/doxorubicin/cyclophosphamide/prednisone, ICE ifosamide/etopside/carboplatin, MCP mitoxantrone/chlorambucil/prednisolone, HCVAD fractionated cyclophopshamide/vincristine/doxorubicin/dexamethasone

Reference	Indication	Dose and schedule^a	No. of patients^b	Response rate
Anthracycline-based regimens: indolent lymphoma
[41]	Front-line or relapsed/refractory low-grade B-cell lymphoma	(R+CHOP) × 6	40	ORR=95%
[44]				In completely treated patients
				ORR=100% (63% CR, 37% PR)
				Median DR: 63.6+ months
[76]	Front-line follicular NHL	Randomized, two cohorts:	82^c	ORR=97% (57% CR, 40% PR)
		R, 375 mg/m², 4× weekly then:		After a median of 15 months follow-up, 87% of patients are progression free
		1. (R+CHOP) × 3 OR
		2. (R+CVP) × 3
[113]	Front-line follicular NHL	CHOP × 6	84	ORR=72%
		Followed by R, 375 mg/m², 4× weekly		(54% CR and Cru; 18% PR); 2-year progression-free survival=76%
		Followed by R, 375 mg/m², 4× weekly		2-year overall survival=95%
[131]	Relapsed or refractory low-grade NHL	RCD × median of 6	10	ORR=100% (40% CR, 60% PR)
[131]	Relapsed or refractory low-grade NHL	RCD × median of 6	10	Median DR=not reached at 10+ months
[81]	Advanced indolent NHL, lymphoplasmacytic and MCL	Randomized, two cohorts:	106^c	ORR=82% (40% CR, 42%PR)
		1. (R+MCP) × 8 OR	All patients	Results similar and unblinded
		2. MCP × 8	All patients	Median DR=not available
Anthracycline-based regimens: chronic lymphocytic leukemia
[135]	Relapsed/refractory CLL and autoimmune hematological disease	RCD × 1	4	All patients responded
[135]		RCD × 1	4	Median DR=not available
[72]	Relapsed/refractory advanced chronic CLL	RCD × median of 4	22	ORR=77% (36% CR, 41% PR)
[72]	Relapsed/refractory advanced chronic CLL	RCD × median of 4	22	Median survival: not reached at 27+ months
Anthracycline-based regimens: aggressive lymphoma
[37]	Front-line diffuse large B-cell lymphoma: elderly patients	Randomized, two cohorts:	202 (R-CHOP) 197 (CHOP)	CHOP+R: ORR=82% (76% CR, 7% PR)
		1. (R+CHOP) × 8 OR		At 2 years, 70% survival
		2. CHOP × 8		CHOP alone: ORR=66% (63% CR, 3% PR)
[177]	Front-line advanced aggressive NHL	(R+CHOP) × 6	33	ORR=94% (61% CR, 33% PR)
[177]	Front-line advanced aggressive NHL	(R+CHOP) × 6	33	Median DR=not reached after 26+ months
[185]	Front-line or relapsed/refractory aggressive NHL	(R+EPOCH) × a minimum of 6	20^c	Front-line patients: ORR=85% (85% CR)
			Front line	At median of 12 months, 85% progression-free survival
			14^c Relapsed/refractory	Relapsed/refractory patients: ORR=85% (64% CR, 21% PR)
[85]	Front-line mantle-cell lymphoma	(R+CHOP) × 6	40	ORR=96% (48% CR+CRu, 48% PR)
[85]	Front-line mantle-cell lymphoma	(R+CHOP) × 6	40	Median progression-free survival: 16.6 months
[96]	Relapsed or refractory diffuse large B-cell lymphoma	(R+ICE) × 3	31^c	ORR=81% (55% CR, 26% PR)
[96]	Relapsed or refractory diffuse large B-cell lymphoma	(R+ICE) × 3	31^c	Median DR=not available
[175]	Front-line diffuse large-cell lymphoma or MCL	(CHOP+R+GMCSF) × 6	14^c	ORR=100% (21% CR, 79% PR)
[175]	Front-line diffuse large-cell lymphoma or MCL	(CHOP+R+GMCSF) × 6	14^c	Median DR=not available
[166]	Front-line Burkitt's, Burkitt's-like leukemia, or lymphoma	[R (375 mg/m², two doses within 12 days)+HCVAD] × 4	15^c	CR=93%
[166]	Front-line Burkitt's, Burkitt's-like leukemia, or lymphoma	[R (375 mg/m², two doses within 12 days)+HCVAD] × 4	15^c	1 year estimated disease-free survival 86%

^aUnless otherwise noted, one infusion of rituximab (375 mg/m²) is included in each combination cycle

^bPatients in the intent-to-treat population are listed, unless otherwise noted

^cEvaluable patients only